ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0862 • ACR Convergence 2020

    Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

    Teun van Gelder1, Robert Huizinga2, Neil Solomons2 and Laura Lisk3, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
  • Abstract Number: 0861 • ACR Convergence 2020

    Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients

    Samantha Slight-Webb1, Kevin Thomas1, Rufei Lu1, Susan Macwana1, Joan Merrill1, Cristina Arriens1, Eliza Chakravarty1, Teresa Aberle1, Holden Maecker2, Paul Utz3, Joel Guthridge1 and Judith James4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, 3Stanford University School of Medicine, Stanford, CA, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Hydroxychloroquine (HCQ) has been used for decades to treat systemic lupus erythematosus (SLE) and is associated with decreased lupus flares and damage. However, despite…
  • Abstract Number: 0867 • ACR Convergence 2020

    Hydroxychloroquine Use Predicts Significantly Higher Patient and Graft Survival in Post-Renal Transplant Lupus Nephritis Patients

    Shivani Garg1, Tripti Singh1, Sarah Panzer2 and Christie Bartels3, 1UW Madison, Madison, WI, 2UW-Madison, Madison, 3University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is a pivotal therapy for lupus nephritis (LN) as it contributes to 65% lower mortality and 84% lower renal damage compared to…
  • Abstract Number: 0866 • ACR Convergence 2020

    Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies

    Joan Merrill1, Matthew Studham2, Eric Morand3, Aida Aydemir2, Cristina Vazquez Mateo2, Alex Rolfe2, Amy Kao2 and Robert Townsend2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…
  • Abstract Number: 0872 • ACR Convergence 2020

    Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia

    Ilze Vinkalna1, Inita Bulina2, Natalija Vellere2, Kristine Ivanova2, Pauls Rubins2, Renate Diura2, Santa Mikena2, Julija Zepa2 and Daina Andersone2, 1Pauls Stradins Clinical University Hospital, Rīga, Latvia, 2Pauls Stradins Clinical University Hospital, Riga

    Background/Purpose: To determine the factors influencing hospitalisation duration, re – hospitalisation (more than 1 hospitalisation during the study period), frequency of the usage of corticosteroids…
  • Abstract Number: 0874 • ACR Convergence 2020

    A Multi-Center, Randomized, Double-blind, Placebo-controlled Dose-ranging Study Evaluating Efficacy and Safety of SHR-1314 in Subjects with Moderate-to-Severe Plaque Psoriasis

    Chunlei Zhang1, Kexiang Yan2, Qingchun Diao3, Qing Guo4, Hongzhong Jin5, Sen Yang6, Xiang Chen7, Tiechi Lei8, Jianhua Wu9, Hong Yu10, Min Zheng11, Xinghua Gao12, Robert Sinclair13, Delilah Alonso14, Yi Zhu15, Qian Xu15 and Jinhua Xu2, 1Department of Dermatology, Peking University Third Hospital, Beijing, China (People's Republic), 2Huashan Hospital Affiliated to Fudan University, Shanghai, China (People's Republic), 3Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China (People's Republic), 4Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (People's Republic), 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), 6The First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), 7Xiangya Hospital, Central South University, Changsha, China (People's Republic), 8Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan, China (People's Republic), 9Changhai Hospital of Shanghai, Shanghai, China (People's Republic), 10Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), 11The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic), 12The 1st Hospital of China Medical University, Shenyang, China (People's Republic), 13Sinclair Dermatology, East Melbourne, Australia, 14Revival Research, Doral, 15Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China (People's Republic)

    Background/Purpose: SHR-1314 is a humanized monoclonal immunoglobulin (IgG1/κ isotype) targeting human interleukin-17A (IL-17A). Preliminary data from phase I study has shown that single dose of…
  • Abstract Number: 0869 • ACR Convergence 2020

    Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine

    Celline Almeida-Brasil1, John Hanly2, Murray Urowitz3, Ann Clarke4, Rosalind Ramsey-Goldman5, Caroline Gordon6, Michelle Petri7, Ellen M Ginzler8, Daniel J Wallace9, Sang-Cheol Bae10, Juanita Romero-Díaz11, Mary Ann Dooley12, Christine A. Peschken13, David Isenberg14, Anisur Rahman14, Susan Manzi15, Søren Jacobsen16, S. Sam Lim17, Ronald Van Vollenhoven18, Ola Nived19, Andreas Jönsen19, Diane Kamen20, Cynthia Aranow21, Guillermo Ruiz-Irastorza22, Jorge Sanchez-Guerrero23, Dafna Gladman24, Paul Fortin25, Graciela Alarcón26, Joan Merrill27, Kenneth Kalunian28, Manuel Ramos-Casals29, Kristjan Steinsson30, Asad Zoma31, Anca Askanase32, Munther Khamashta33, Ian Bruce34, Murat Inanc35 and Sasha Bernatsky36, 1McGill University, Montreal, Canada, 2QEII Health Sciences Centre, Halifax, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University of Calgary, Calgary, Canada, 5Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 6University of Birmingham, Birmingham, England, United Kingdom, 7Johns Hopkins University School of Medicine, Baltimore, 8SUNY Downstate Health Sciences University, Brooklyn, 9Cedars-Sinai Medical Center, Beverly Hills, CA, 10Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 11Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 12UNC Health, Chapel Hil, 13University of Manitoba, Winnipeg, Canada, 14University College London, London, United Kingdom, 15Temple University, Philadelphia, 16University of Copenhagen, Copenhagen, Denmark, 17Emory University, Atlanta, GA, 18University of Amsterdam, Amsterdam, Netherlands, 19Lund University, Lund, Sweden, 20Medical University of South Carolina, Charleston, SC, 21Feinstein Institutes for Medical Research, Manhasset, NY, 22Hospital Universitario Cruces, Barakaldo, Spain, 23University of Toronto, Toronto, Canada, 24Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 25CHU de Quebec - Universite Laval, Quebec, Canada, 26Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, 27New York University, New York, 28University of California San Diego, La Jolla, CA, 29University of Barcelona, Barcelona, Spain, 30Reykjavik University, Reykjavik, Iceland, 31University of Glasgow, Glasgow, United Kingdom, 32Columbia University College of Physicians & Surgeons, New York, NY, 33King's College London, London, United Kingdom, 34The University of Manchester, Manchester, United Kingdom, 35Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 36The Research Institute of the McGill University Health Centre, Montreal, ON, Canada

    Background/Purpose: Despite the beneficial effects of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE), retinal toxicity is a concern. Factors associated with retinal toxicity have been…
  • Abstract Number: 0864 • ACR Convergence 2020

    Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus

    Lisa Zhu1, Manpreet Singh2, Caroline Siegel3, Lori Sahakian2, Jennifer Grossman4 and Maureen McMahon5, 1University of California, Los Angeles, Van Nuys, CA, 2University of California, Los Angeles, Los Angeles, CA, 3Hospital for Special Surgery, New York, NY, 4University of California, Los Angeles, Sherman Oaks, CA, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated a wide array of beneficial effects in patients with systemic lupus erythematosus (SLE), with regard to disease activity, flare rates,…
  • Abstract Number: 0877 • ACR Convergence 2020

    Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib

    Uta Kiltz1, Joachim Sieper2, Atul Deodhar3, Patrick Zueger4, In-Ho Song4, Naijun Chen4 and Désirée van der Heijde5, 1Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Herne, Germany, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Oregon Health & Science University, Portland, OR, 4AbbVie Inc., North Chicago, IL, 5Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…
  • Abstract Number: 0880 • ACR Convergence 2020

    Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks

    Georg Schett1, Filip Van den Bosch2, Xenofon Baraliakos3, David Sandoval4, Vladimir Geneus4, Rebecca Bolce4, Soyi Liu-Leage5, Andris Kronbergs4 and Philip Mease6, 1Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 2Ghent University Hospital, Ghent, Belgium, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 4Eli Lilly and Company, Indianapolis, 5Eli Lilly and Company, Indianapolis, IN, 6Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of…
  • Abstract Number: 0881 • ACR Convergence 2020

    Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study

    Irene van der Horst-Bruinsma1, Rianne van Bentum1, Frank Verbraak2, Thomas Rath3, James Rosenbaum4, Bengt Hoepken5, Oscar Irvin-Sellers6, Thomas Kumke5, Lars Bauer5 and Martin Rudwaleit7, 1Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 2Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 3St Franziskus-Hospital, Münster, Germany, 4Oregon Health & Science University, Portland, OR, 5UCB Pharma, Monheim am Rhein, Germany, 6UCB Pharma, Slough, United Kingdom, 7Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany

    Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…
  • Abstract Number: 0876 • ACR Convergence 2020

    Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials

    Marina Magrey1, Kurt de Vlam2, Rebecca Bolce3, Soyi Liu-Leage4, Danting Zhu4, Theresa Hunter3, David Sandoval3 and Irene van der Horst-Bruinsma5, 1Case Western Reserve University School of Medicine, Cleveland, OH, 2Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 3Eli Lilly and Company, Indianapolis, 4Eli Lilly and Company, Indianapolis, IN, 5Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to placebo in the treatment of patients with axial spondyloarthritis (axSpA) (Dougados M et…
  • Abstract Number: 0884 • ACR Convergence 2020

    Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Patrick Zueger4 and Alexis Ogdie5, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
  • Abstract Number: 0879 • ACR Convergence 2020

    Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice

    Esther Beckers1, Annelies Boonen1, Casper Webers1, Peter Ten Klooster2, Harald Vonkeman2, Monique Efde3 and Astrid van Tubergen4, 1Maastricht University Medical Center, Maastricht, Netherlands, 2University of Twente, Enschede, Netherlands, 3VieCuri Medical Center, Venlo, Netherlands, 4Maastricht University Medical Center, Maastricht

    Background/Purpose: Treat-to-target (T2T) management strategies in inflammatory rheumatic diseases aim to prevent damage and improve overall functioning and health by treating patients towards a predefined…
  • Abstract Number: 0771 • ACR Convergence 2020

    Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up

    Consuelo Romero-Sanchez1, Juan Manuel Bello-Gualtero2, Juliette De Avila3, Gloria Lafaurie4, Philipe Chalem Choueka5, Cesar Pacheco Tena6, Sebastian Giraldo-Q7, Jeimmy Andrea Chaparro-Sanabria8, Alejandro Ramos-Casallas3, Lorena Chila-M3 and Wilson Bautista-Molano9, 1Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 2Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 3Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, 4Universidad El Bosque, Basic Oral Research Unit – UIBO, School of Dentistry, Bogotá D.C., Colombia, 5Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, 6Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, 7Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogota D.C., Colombia, 8Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, 9University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia

    Background/Purpose: In rheumatoid arthritis (RA), autoimmunity towards citrullinated peptides driven the hypothesis, in which periodontal disease (PD) is strongly related to the pathogenesis. Given the…
  • « Previous Page
  • 1
  • …
  • 683
  • 684
  • 685
  • 686
  • 687
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology